keyword
https://read.qxmd.com/read/38728546/what-should-healthcare-systems-consider-when-modernizing-call-centers-early-considerations-from-the-veterans-health-administration
#1
JOURNAL ARTICLE
Caroline Gray, Barbara Lerner, Jacqueline Egelfeld, Jada Robinson, Tracy Urech, Anita Vashi
GOAL: Growing numbers of hospitals and payers are using call centers to answer patients' clinical and administrative questions, schedule appointments, address billing issues, and offer supplementary care during public health emergencies and national disasters. In 2020, the Veterans Health Administration (VA) implemented VA Health Connect, an enterprise-wide initiative to modernize call centers. VA Health Connect is designed to improve the care experience with the convenience, flexibility, and simplicity of a single toll-free number connected to a range of 24/7 virtual services...
May 2024: Journal of Healthcare Management / American College of Healthcare Executives
https://read.qxmd.com/read/38727769/aso-visual-abstract-payer-negotiated-price-variation-and-relationship-to-surgical-outcomes-for-the-most-common-cancers-at-nci-designated-cancer-centers
#2
JOURNAL ARTICLE
Roshun Sankaran, John O'Connor, Ushapoorna Nuliyalu, Adrian Diaz, Hari Nathan
No abstract text is available yet for this article.
May 10, 2024: Annals of Surgical Oncology
https://read.qxmd.com/read/38727185/incidence-and-prevalence-of-registered-hypertension-in-poland
#3
JOURNAL ARTICLE
Urszula Cegłowska, Monika Burzyńska, Aleksander Prejbisz, Janina Stępińska, Ryszard Gellert, Jarosław Pinkas, Piotr Jankowski
UNLABELLED: Introduction  Hypertension is a major factor related to morbidity and mortality in the middle and high income countries. OBJECTIVES: The aim of the study was to assess the incidence and prevalence of registered hypertension in Poland in 2018-2022. PATIENTS AND METHODS: We used the public payer claims database to assess incidence and prevalence of registered hypertension. Hypertension was defined using International Classification of Diseases 10th Revision codes from I10 to I15...
May 8, 2024: Polish Archives of Internal Medicine
https://read.qxmd.com/read/38727179/hepatitis-c-treatment-among-primary-care-and-specialty-providers-a-single-center-study-2015-to-2022
#4
JOURNAL ARTICLE
Anna Scialli, Sammy Saab, Anabel Salimian, Debika Bhattacharya, David Goodman-Meza
INTRODUCTION: Despite national goals to eliminate Hepatitis C (HCV) and the advancement of curative, well-tolerated direct-acting antiviral (DAAs) regimens, rates of HCV treatment have declined nationally since 2015. Current HCV guidelines encourage treatment of HCV by primary care providers (PCPs). Payors have reduced restrictions to access DAAs nationally and in California however it remains unclear if the removal of these restrictions has impacted the proportion of PCPs prescribing DAAs at a health system level...
2024: Journal of Primary Care & Community Health
https://read.qxmd.com/read/38726966/cost-analysis-of-bladder-catheterization-after-pelvic-floor-surgery
#5
JOURNAL ARTICLE
Anouk Benseler, Zi Ying Zhao, Muhammad Harris Sheikh, Brian Chan, George Tomlinson, Colleen D McDermott
IMPORTANCE: Approximately 15-45% of female patients develop transient postoperative urinary retention (POUR) following pelvic reconstructive surgery. Catheter options for bladder drainage include transurethral indwelling catheter (TIC), intermittent self-catheterization (ISC), and suprapubic tube (SPT). Each strategy has risks and benefits; none have been shown to be clinically superior, and to date, no comprehensive comparative economic analysis has been published. OBJECTIVE: The objective of this study was to evaluate the cost of these different bladder catheterization strategies after transvaginal pelvic surgery...
May 10, 2024: Urogynecology (Phila)
https://read.qxmd.com/read/38724960/cost-utility-analysis-of-add-on-vericiguat-for-the-treatment-of-chronic-heart-failure-with-reduced-ejection-fraction-in-china
#6
JOURNAL ARTICLE
Lu Wang, Xuechen Huo, Haiyan Sun, Feiyu Liu, Ruiqin Huang, Quan Zhao
OBJECTIVE: This study aimed to evaluate the cost-utility of the addition of vericiguat for treating chronic heart failure (CHF) in China from the healthcare payer's perspective. METHODS: A Markov model was built to estimate the cost and utility of treating CHF using vericiguat plus standard treatment (vericiguat group) vs. standard treatment alone (standard treatment group). The clinical parameters (mortality of cardiovascular and hospitalization rate of HF) were calculated according to the VICTORIA clinical trial...
May 9, 2024: BMC Public Health
https://read.qxmd.com/read/38722496/real-world-treatment-patterns-among-patients-with-type-2-diabetes-mellitus-initiating-treatment-with-oral-semaglutide
#7
JOURNAL ARTICLE
Caroline Swift, Monica S Frazer, Noelle N Gronroos, Andrew Sargent, Michael Leszko, Erin Buysman, Sara Alvarez, Tyler J Dunn, Josh Noone, Mico Guevarra
INTRODUCTION: The treatment landscape for type 2 diabetes mellitus (T2DM) is complex and constantly evolving, and real-world evidence of prescribing patterns is limited. The objectives of this study were to characterize lines of therapy (LOTs), calculate the length of time spent on each LOT, and identify the reasons for the LOT end among patients who initiated oral semaglutide for T2DM. METHODS: This retrospective, claims-based study included commercial and Medicare Advantage adults with T2DM...
May 9, 2024: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://read.qxmd.com/read/38722493/routine-functional-testing-or-standard-care-in-high-risk-patients-after-percutaneous-coronary-intervention
#8
REVIEW
Nouman Arshad, Indah Sukmawati, Upul Wickramarachchi, Shrilla Banerjee, Fathima Aaysha Cader
PURPOSE OF REVIEW: This review aimed to collate the available evidence on outcomes following routine functional stress testing vs standard of care (i.e. symptom-guided stress testing) in high-risk patients following percutaneous coronary intervention (PCI). RECENT FINDINGS: The most recent pragmatic POST-PCI trial provided randomized evidence showing that routine functional stress testing post-PCI did not lead to a reduction in 2-year ischemic cardiovascular events or all-cause mortality, as compared to a symptom-guided standard-of-care approach...
May 9, 2024: Current Cardiology Reports
https://read.qxmd.com/read/38721189/rising-cardiovascular-mortality-despite-increased-resource-utilization-insights-from-the-nationwide-inpatient-sample-database
#9
JOURNAL ARTICLE
Chikodili Nebuwa, Omouyi J Omoike, Adeniyi Fagbenro, Fidelis Uwumiro, Efe Erhus, Victory Okpujie, Ifeoluwa Fadeyibi, Onyedikachi Adike, Agatha O Osadolor
Introduction The global burden of cardiovascular disease (CVD) has risen over the past decade, potentially escalating resource utilization, morbidity, and mortality. We analyzed trends in hospitalization for CVDs, outcomes of hospitalizations, and the impact of the COVID-19 pandemic on CVD hospitalizations between 2016 and 2020. Methods Adult CVD hospitalizations recorded in the 2016-2020 nationwide inpatient sample (NIS) were identified using major diagnostic categories (MDC- class 5). The NIS is the largest all-payer repository of all hospitalizations in the USA within a calendar year...
April 2024: Curēus
https://read.qxmd.com/read/38719438/cost-effectiveness-of-emicizumab-prophylaxis-for-haemophilia-a-with-inhibitors-an-adaptive-health-technology-assessment-for-the-indian-setting
#10
JOURNAL ARTICLE
Sitanshu Sekhar Kar, Parthibane Sivanantham, Vanessa Ravel, Abha Mehndiratta, Kirti Tyagi, Daniel A Ollendorf
OBJECTIVE: To assess the cost-effectiveness of emicizumab prophylaxis for patients having haemophilia A with inhibitors in the Indian context using an adaptive health technology assessment (aHTA) methodology. DESIGN: Economic evaluation using multiple approaches aimed at adjusting previously generated cost-effectiveness results based on (1) price differences only ('simple') and (2) differences in cost and expected treatment duration ('moderate') and differences in cost, inflation and life expectancy ('complex')...
May 6, 2024: BMJ Evidence-Based Medicine
https://read.qxmd.com/read/38719274/assessment-of-socioeconomic-and-racial-differences-in-patients-undergoing-concurrent-gynecologic-oncology-and-urogynecology-surgeries-a-national-inpatient-sample-nis-database-study
#11
JOURNAL ARTICLE
Ioana Marcu, Eric M McLaughlin, Silpa Nekkanti, Wafa Khadraoui, Julia Chalif, Jessica Fulton, David O'Malley, Laura M Chambers
OBJECTIVE: To assess social determinants of health impacting patients undergoing gynecologic oncology versus combined gynecologic oncology and urogynecology surgeries. METHODS: We identified patients who underwent gynecologic oncology surgeries from 2016 to 2019 in the National Inpatient Sample using the International Classification of Diseases-10 codes. Demographics, including race and insurance status, were compared for patients who underwent gynecologic oncology procedures only (Oncologic) and those who underwent concurrent incontinence or pelvic organ prolapse procedures (Urogynecologic-Oncologic)...
May 6, 2024: International Journal of Gynecological Cancer
https://read.qxmd.com/read/38717044/evaluating-the-cost-effectiveness-of-voclosporin-for-the-treatment-of-lupus-nephritis-in-the-united-states
#12
JOURNAL ARTICLE
Lisa Kennedy, Ernie Lee, Ronald Flauto, Victoria Atencio, Vanessa Birardi
BACKGROUND: Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus; up to 30% of patients with LN will develop end-stage kidney disease (ESKD). One of the main treatment goals for LN is preservation of kidney function, with early decreases in proteinuria associated with improved long-term outcomes. Voclosporin, a second-generation calcineurin inhibitor, was approved in the United States in 2021 for the treatment of active LN combined with background immunosuppression...
May 8, 2024: Journal of Managed Care & Specialty Pharmacy
https://read.qxmd.com/read/38716656/the-value-of-microvascular-breast-reconstruction-cost-equivalence-of-tram-and-diep-flaps-implications-in-the-era-of-cms-reforms
#13
COMPARATIVE STUDY
Jose A Foppiani, Angelica Hernandez Alvarez, Erin J Kim, Maria J Escobar-Domingo, Iulianna C Taritsa, Kirsten A Schuster, Daniela Lee, Olivia A Ho, Brian Rinker, Bernard T Lee, Samuel J Lin
BACKGROUND: Recent CMS billing changes have raised concerns about insurance coverage for deep inferior epigastric perforator (DIEP) flap breast reconstruction. This study compared the costs and utilization of transverse rectus abdominis myocutaneous (TRAM), DIEP, and latissimus dorsi (LD) flaps in breast reconstruction. METHOD: The study utilized the National Inpatient Sample database to identify female patients who underwent DIEP, TRAM, and LD flap procedures from 2016 to 2019...
May 2024: Microsurgery
https://read.qxmd.com/read/38716573/prescribing-patterns-of-nonrecommended-medications-for-children-with-acute-covid-19
#14
JOURNAL ARTICLE
Julianne E Burns, Alex Dahlen, Laura L Bio, Lisa J Chamberlain, Hannah K Bassett, Raksha Ramaraj, Hayden T Schwenk, Ronald J Teufel, Alan R Schroeder
OBJECTIVE: Repurposed medications for acute coronavirus disease 2019 (COVID-19) continued to be prescribed after results from rigorous studies and national guidelines discouraged use. We aimed to describe prescribing rates of nonrecommended medications for acute COVID-19 in children, associations with demographic factors, and provider type and specialty. METHODS: In this retrospective cohort of children <18 years in a large United States all-payer claims database, we identified prescriptions within 2 weeks of an acute COVID-19 diagnosis...
May 8, 2024: Pediatrics
https://read.qxmd.com/read/38715764/leveraging-decentralized-clinical-trial-management-systems-dctms-to-advance-science-exploring-challenges-related-to-the-diffusion-of-innovation-and-its-execution
#15
JOURNAL ARTICLE
Rama Krishna Rao
Decentralized clinical trials (DCTs) recently gained attention in research necessary for drug development. While the COVID-19 pandemic proved to be a challenging time in this arena, drug development was a critical area of emphasis in the rapid advancement of vaccines. The DCTs were necessary to allow research activities to occur across many locations. The use of DCTs can profoundly impact reshaping healthcare by enabling participants to partake in clinical trials remotely; however, implementation challenges must be considered as technology expands...
2024: Blockchain in healthcare today
https://read.qxmd.com/read/38714970/lower-comorbidity-scores-and-severity-levels-in-veterans-health-administration-hospitals-a-cross-sectional-study
#16
JOURNAL ARTICLE
Matthew P Dizon, Adam Chow, Michael K Ong, Ciaran S Phibbs, Megan E Vanneman, Yue Zhang, Jean Yoon
BACKGROUND: Previous studies found that documentation of comorbidities differed when Veterans received care within versus outside Veterans Health Administration (VHA). Changes to medical center funding, increased attention to performance reporting, and expansion of Clinical Documentation Improvement programs, however, may have caused coding in VHA to change. METHODS: Using repeated cross-sectional data, we compared Elixhauser-van Walraven scores and Medicare Severity Diagnosis Related Group (DRG) severity levels for Veterans' admissions across settings and payers over time, utilizing a linkage of VHA and all-payer discharge data for 2012-2017 in seven US states...
May 8, 2024: BMC Health Services Research
https://read.qxmd.com/read/38713873/understanding-the-influence-of-single-payer-health-insurance-on-socioeconomic-disparities-in-total-hip-arthroplasty-tha-utilization-a-transnational-analysis
#17
JOURNAL ARTICLE
Bella Mehta, Kaylee Ho, J Alex B Gibbons, Vicki Ling, Susan Goodman, Michael Parks, Bheeshma Ravi, Fei Wang, Said Ibrahim, Peter Cram
OBJECTIVE: Access to care varies between countries. It is theorized that income-based disparities in access may be reduced in countries with universal health insurance relative to the United States, but data are currently limited. We hypothesized that income-based differences in total hip arthroplasty (THA) utilization and outcomes would be larger in the United States than in Canada. METHODS: We retrospectively compared all patients undergoing THA from 2012 to 2018 in Pennsylvania, the United States, and Ontario, Canada...
May 3, 2024: Journal of the American Academy of Orthopaedic Surgeons
https://read.qxmd.com/read/38713445/comparative-evaluation-of-postoperative-outcomes-and-expenditure-between-robotic-and-conventional-single-level-lumbar-fusion-surgery-a-comprehensive-analysis-of-nationwide-inpatient-sample-data
#18
JOURNAL ARTICLE
David Maman, Assil Mahamid, Binyamin Finkel, Hadar Gan-Or, Linor Fournier, Yaron Berkovich, Eyal Behrbalk
INTRODUCTION: In this study, we investigate the evolution of lumbar fusion surgery with robotic assistance, specifically focusing on the impact of robotic technology on pedicle screw placement and fixation. Utilizing data from the Nationwide Inpatient Sample (NIS) covering 2016 to 2019, we conduct a comprehensive analysis of postoperative outcomes and costs for single-level lumbar fusion surgery. Traditionally, freehand techniques for pedicle screw placement posed risks, leading to the development of robotic-assisted techniques with advantages such as reduced misplacement, increased precision, smaller incisions, and decreased surgeon fatigue...
May 7, 2024: European Spine Journal
https://read.qxmd.com/read/38712895/cost-effectiveness-analysis-of-mosunetuzumab-for-treatment-of-relapsed-or-refractory-follicular-lymphoma-after-two-or-more-lines-of-systemic-therapy-in-the-united-states
#19
JOURNAL ARTICLE
Matthew Matasar, Javier Sanchez Alvarez, Hélène Parisé, Eric Zuk, Danilo Di Maio, Sheila Shapouri, Eunice Kim, Shih-Wen Lin
AIMS: Mosunetuzumab has received accelerated approval by the US Food and Drug Administration for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy. We evaluated the cost-effectiveness of mosunetuzumab for the treatment of R/R FL from a US private payer perspective. MATERIALS AND METHODS: A partitioned survival model simulated lifetime costs and outcomes of mosunetuzumab against seven comparators: axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), tazemetostat (taz, EZH2 wild-type only), rituximab plus lenalidomide (R-Len) or bendamustine (R-Benda), obinutuzumab plus bendamustine (O-Benda), and a retrospective real-world cohort (RW) based on current patterns of care derived from US electronic health records (Flatiron Health)...
May 7, 2024: Journal of Medical Economics
https://read.qxmd.com/read/38712784/first-year-follow-up-costs-of-myocardial-infarction-management-in-poland-from-the-payer-s-perspective
#20
JOURNAL ARTICLE
Andrzej Ciszewski
No abstract text is available yet for this article.
May 7, 2024: Kardiologia Polska
keyword
keyword
22260
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.